What happened with CGC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of Canopy Growth Corporation’s revenue comes from its Canadian adult-use and medical cannabis businesses, which are similar in size. For adult-use sales, provincial and territorial cannabis authorities buy its products for distribution through regulated retail networks. These authorities are the sole wholesalers in their jurisdictions, making them essential to reaching consumers. Their supply contracts have no minimum purchase commitments, and they control product listings and pricing and can return products or stop buying.
The medical business sells directly to registered Canadian patients through the Spectrum Therapeutics and Abba Medix online shops and ships orders to their registered addresses. Clinics help patients access treatment and ongoing support. Veterans Affairs Canada pays directly for covered veterans’ purchases. The company also supplies medical cannabis in Germany, Poland and Australia, though international cannabis sales contribute less revenue than either Canadian business.
A separate, substantial revenue source is Storz & Bickel, which designs, manufactures and sells devices that vaporize cannabis or dry herbs, along with accessories, internationally. Cannabis operations depend on maintaining government licenses and complying with local production, import and sales rules. U.S. federal law and stock-exchange requirements constrain the company’s U.S. cannabis activities: its Canopy USA shares have no voting or dividend rights, and the current structure does not allow it to direct Canopy USA or participate in its U.S. cannabis operations.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Aurora Cannabis and Canopy Growth compete for Canadian medical patients buying directly from them and for international medical cannabis demand. Watch Aurora’s medical gross profit: it expects a federal reimbursement change effective April 1, 2026 to cut reimbursement by approximately 30%, a pressure worth watching alongside Canopy’s reimbursed veteran sales.
Tilray Brands and Canopy Growth compete for Canadian adult-use cannabis buyers and international medical patients. Watch Tilray’s cannabis business rather than its overall results, which also reflect substantial beverage sales and distribution of pharmaceutical and wellness products.
Organigram Global competes with Canopy Growth for Canadian consumers buying flower, infused pre-rolls, gummies and hash. Watch how Organigram’s brands perform across price tiers in those products, where Canopy is trying to build loyalty through a differentiated range.
Cronos competes with Canopy Growth to sell flower, pre-rolls, vapes and edibles to Canadian provincial cannabis wholesalers, which buy products for retail distribution; Cronos sells to private retailers in Saskatchewan instead. Watch its Spinach and Lord Jones sales through these channels for a view of the purchasing and pricing conditions Canopy faces.
Village Farms’ Pure Sunfarms and Rose LifeScience businesses compete with Canopy Growth’s brands for Canadian cannabis buyers. Watch its Canadian cannabis results for signs of wholesale pricing pressure, which has already hurt Canopy’s core flower and pre-roll sales.
Sundial Growers’ SNDL cannabis operations grow and sell products competing with Canopy Growth for Canadian adult-use buyers and medical patients. Separate those results from its liquor stores, and watch sales to consumers at Value Buds and Spiritleaf for another view of adult-use demand.
High Tide’s Canadian cannabis stores serve the adult-use consumers whose spending drives provincial wholesalers’ purchases of Canopy Growth products. Watch its Canadian store sales as a read on that demand, not as evidence that High Tide buys directly from Canopy.
IM Cannabis competes with Canopy Growth for German medical patients by importing cannabis through Adjupharm and selling it to licensed pharmacies. Watch its German pharmacy sales for a view of the medical market where Canopy says patients mainly use dried flower.
Sundial Growers Inc. earningsSNDL
SNDL's cannabis business and sales at Value Buds and Spiritleaf show Canadian adult-use demand at both the supplier and retail levels.
Read SNDL's cannabis business alongside consumer sales at Value Buds and Spiritleaf. If both strengthen, shoppers are pulling more product through retail, a supportive demand signal for Canopy Growth's adult-use products too. If store sales weaken, consumers are providing less support even if supplier sales have not yet shown it. This helps distinguish softer shopper demand from a change limited to suppliers' sales.
Aurora Cannabis Inc. earningsACB
Aurora Cannabis's medical gross profit will show whether it can preserve profit per sale in medical markets where it competes with Canopy Growth for patients.
Read Aurora Cannabis's medical sales alongside its medical gross profit. Growing sales with gross profit holding up would show it can still earn from medical products, giving competition for patients a profitable footing. If sales hold but gross profit narrows, reimbursement terms or product mix may be squeezing margins, so sales growth alone would not show stronger economics. This tests a competitor's business, not Canopy Growth's own veteran sales or reimbursement income.
Cronos Group Inc. earningsCRON
Cronos's report will show how provincial cannabis wholesalers are buying and pricing products, a channel Canopy Growth also relies on.
Focus on Cronos sales through provincial wholesalers, while keeping in mind that it also sells through private retailers in Saskatchewan. Stable or rising wholesaler-channel sales suggest buyers are still purchasing these products, supporting a route to market that Canopy Growth also uses. Weakening sales may point to tougher purchasing or pricing conditions for Canopy Growth's provincial supply channel. Cronos's private retail sales are not a direct measure of provincial-wholesaler buying.
Canopy Growth Corporation earningsThis company
Canopy Growth's report will show whether sales of cannabis products and Storz & Bickel vaporizers are turning into more gross profit.
Read revenue and gross margin together for the Cannabis and Storz & Bickel businesses; gross margin is the share of sales left after direct product costs. Rising revenue with stable or improving margins means sales growth is not being swallowed by costs or product mix. Falling revenue or narrower margins means sales are leaving less gross profit behind. Together, the figures show whether Canopy Growth is converting product sales into firmer gross profit.
IM Cannabis Corp. earningsIMCC
IM Cannabis's German pharmacy sales will show how medical patients are buying in a market Canopy Growth also serves.
Watch how IM Cannabis's sales through licensed German pharmacies change. Rising sales support the view that demand through this medical channel is holding up, a positive market signal for Canopy Growth, which also serves German patients. Falling sales mean less support from the market, but this report alone cannot separate patient demand from competition or IM Cannabis's own performance. The takeaway is whether the German market is providing demand support, not how Canopy Growth itself performed.
